Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
43
-
Total 13F principal, excl. options
-
407M
-
Principal change
-
+397M
-
Total reported value, excl. options
-
$456M
-
Value change
-
+$445M
-
Number of buys
-
42
-
Number of sells
-
-1
-
Price
-
$1.12
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2016
43 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2016.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 43 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $407M of principal
.
Largest 10 bondholders include CITADEL ADVISORS LLC ($56M of principal), WOLVERINE ASSET MANAGEMENT LLC ($42.8M of principal), UBS ASSET MANAGEMENT AMERICAS INC ($40.5M of principal), Allianz Asset Management GmbH ($24.8M of principal), LINDEN ADVISORS LP ($23.4M of principal), HIGHFIELDS CAPITAL MANAGEMENT LP ($23M of principal), Capital World Investors ($22.6M of principal), OAKTREE CAPITAL MANAGEMENT LP ($18.9M of principal), MACKAY SHIELDS LLC ($17.3M of principal), and LAZARD ASSET MANAGEMENT LLC ($16.5M of principal).
This table shows the top 43 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.